Last reviewed · How we verify
V3-P
At a glance
| Generic name | V3-P |
|---|---|
| Also known as | oral tableted therapeutic vaccine |
| Sponsor | Immunitor LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial (NA)
- Differences Between Two Type Implants in Post-extraction Alveolus (NA)
- Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension (PHASE3)
- Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer (PHASE1, PHASE2)
- Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V3-P CI brief — competitive landscape report
- V3-P updates RSS · CI watch RSS
- Immunitor LLC portfolio CI